Storm Therapeutics, a drug discovery group, has named Professor Paul Workman as its director, it was reported yesterday.

Presently, Workman serves The Institute of Cancer Research as its president and chief executive officer and has previously served as head of the division of cancer therapeutics at Cancer Research UK.

He said, 'I am delighted to be joining the board of Storm and working with the company in this exploding area of biology. RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies. I look forward to working with the board to help guide Storm's innovative research programmes, adding my experience from drug discovery in academia, pharma and biotech.'